Clinical Trial Update: DHA Brain Delivery Trial [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brain delivery of docosahexaenoic acid (DHA) to assess Alzheimer's disease risk has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Docosahexaenoic acid (docosahexaenoic acid)

Snippet

Sponsor: University of Southern California | Conditions: Brain DHA Delivery and Alzheimer's Disease Risk | Phase 2 | Status: COMPLETED